Abstract:Alzheimer's disease (AD) is the most common form of neurodegenerative disease and disability in the elderly; it is estimated to account for 60%-70% of all cases of dementia worldwide. The most relevant mechanistic hypothesis to explain AD symptoms is neurotoxicity induced by aggregated amyloid-β peptide (Aβ) and misfolded tau protein. These molecular entities are seemingly insufficient to explain AD as a multifactorial disease characterized by synaptic dysfunction, cognitive decline, psychotic symptoms, chronic inflammatory environment within the central nervous system (CNS), activated microglial cells, and dysfunctional gut microbiota. The discovery that AD is a neuroinflammatory disease linked to innate immunity phenomena started in the early nineties by several authors, including the ICC´s group that described, in 2004, the role IL-6 in AD-type phosphorylation of tau protein in deregulating the cdk5/p35 pathway. The "Theory of Neuroimmunomodulation", published in 2008, proposed the onset and progression of degenerative diseases as a multi-component "damage signals" phenomena, suggesting the feasibility of "multitarget" therapies in AD. This theory explains in detail the cascade of molecular events stemming from microglial disorder through the overactivation of the Cdk5/p35 pathway. All these knowledge have led to the rational search for inflammatory druggable targets against AD. The accumulated evidence on increased levels of inflammatory markers in the cerebrospinal fluid (CSF) of AD patients, along with reports describing CNS alterations caused by senescent immune cells in neuro-degenerative diseases, set out a conceptual framework in which the neuroinflammation hypothesis is being challenged from different angles towards developing new therapies against AD. The current evidence points to controversial findings in the search for therapeutic candidates to treat neuroinflammation in AD. In this article, we discuss a neuroimmune-modulatory perspective for pharmacological exploration of molecular targets against AD, as well as potential deleterious effects of modifying neuroinflammation in the brain parenchyma. We specifically focus on the role of B and T cells, immuno-senescence, the brain lymphatic system (BLS), gut-brain axis alterations, and dysfunctional interactions between neurons, microglia and astrocytes. We also outline a rational framework for identifying "druggable" targets for multi-mechanistic small molecules with therapeutic potential against AD.

Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders

Neuroinflammation: A Critical Factor in Neurodegenerative Disorders

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond

The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets

Insights into the Neurodegenerative Process of Alzheimer's Disease: a Role for Mononuclear Phagocyte-Associated Inflammation and Neurotoxicity

Current Knowledge and Therapeutic Implications

Advances in gene therapy approaches targeting neuro-inflammation in neurodegenerative diseases

Modeling the neuroimmune system in Alzheimer's and Parkinson's diseases

Inflammation Mediates Varying Effects in Neurogenesis: Relevance to the Pathogenesis of Brain Injury and Neurodegenerative Disorders

Novel human iPSC models of neuroinflammation in neurodegenerative disease and regenerative medicine

Revisiting the neuroinflammation hypothesis in Alzheimer's disease: a focus on the druggability of current targets

Frontiers of Neurodegenerative Disease Treatment: Targeting Immune Cells in Brain Border Regions

Neuroinflammation, Its Role in Alzheimer’s Disease and Therapeutic Strategies

The role of inflammation in CNS injury and disease

Current understanding of neuroinflammation after traumatic brain injury and cell-based therapeutic opportunities

Recent Advances in Nanotherapeutics for Neurological Disorders

Neurovascular unit, neuroinflammation and neurodegeneration markers in brain disorders

Drugs to Treat Neuroinflammation in Neurodegenerative Disorders

Neuroinflammation of Microglial Regulation in Alzheimer's Disease: Therapeutic Approaches

Neuroinflammation in amyotrophic lateral sclerosis: pathogenic insights and therapeutic implications